Tofersen - A Ray of Hope for ALS Patients: A Mini Review
Hara Prasad Mishra a, * 
a Department of Pharmacology, University College of Medical Sciences, University of Delhi, Delhi, India-110095
	
A R T I C L E  I N F O  	A B S T R A C T  

Received 04 March 2023;
Revised 20 April 2023;
Accepted 18 May 2023.
	Despite thorough investigation, amyotrophic lateral sclerosis (ALS) continues to be a degenerative neurological condition that is inevitably fatal and progresses over time. The limited understanding of the fundamental causes of ALS has posed challenges in addressing the initial biological processes of the disease, resulting in therapeutic interventions typically being applied at later stages of the illness.
The existence of genetic variants in ALS presents a distinctive chance for advancing therapeutic approaches, as studying genetic associations could unveil valuable information about the causes of the disease. In the case of genetic ALS, there is a possibility to explore early intervention by identifying individuals who are at risk and have not yet shown symptoms but possess specific genetic variations that contribute to the condition. Tofersen, an oligonucleotide, has been specifically created to diminish the production of superoxide dismutase 1 (SOD1) protein by breaking down SOD1 mRNA

Keywords:
Amyotrophic lateral sclerosis, superoxide dismutase 1	
An official publication of the Global Pharmacovigilance Society. 

Introduction: 
Mutations in the gene responsible for coding superoxide dismutase 1 (SOD1) are accountable for around 2% of amyotrophic lateral sclerosis (ALS) cases (Bunton-Stasyshyn et al., 2014). Over 200 mutations in the SOD1 gene, which are linked to amyotrophic lateral sclerosis (ALS), have been identified, and these mutations are associated with varying rates of disease progression (Huai et al., 2019). The degeneration of neurons in this disorder is believed to result from the toxic effects caused by the gain of function exhibited by the mutant SOD1 protein (Ekhtiari Bidhendi et al., 2018).
Tofersen is an antisense oligonucleotide that is administered through an intrathecal route, specifically designed to lower the production of SOD1 protein by promoting the degradation of SOD1 messenger RNA through RNaseH-mediated mechanisms (McCampbell et al., 2018).
Pharmacokinetics 
Absorption
Tofersen is administered via intrathecal injection directly into the cerebrospinal fluid (CSF), enabling it to reach the motor neurons in the spinal cord and brain effectively. Intrathecal administration ensures direct delivery to the target site, bypassing potential barriers in other routes of drug administration. This method facilitates optimal absorption and uptake of Tofersen into the affected tissues.
Distribution
Once absorbed into the CSF, Tofersen can distribute throughout the central nervous system (CNS), reaching the motor neurons affected by ALS. The drug is designed to target the SOD1 gene, which plays a crucial role in the progression of ALS. By selectively binding to the messenger RNA (mRNA) produced by the mutated SOD1 gene, Tofersen interferes with the translation process and aims to reduce the production of the harmful SOD1 protein.
Metabolism
Tofersen is an antisense oligonucleotide (ASO) therapy, which is a synthetic molecule designed to specifically target the SOD1 mRNA. As an ASO, Tofersen is not extensively metabolized within the body. Instead, it acts directly on its molecular target, exerting its therapeutic effects through RNA interference. This unique mechanism minimizes potential drug-drug interactions and metabolic variability.
Elimination
The elimination of Tofersen primarily occurs through renal excretion. After fulfilling its therapeutic role, Tofersen is gradually cleared from the body, with the kidneys playing a vital role in excreting any unbound or metabolized drug components. The elimination process ensures that Tofersen's concentration in the body is maintained at an appropriate level, allowing for optimal dosing and therapeutic efficacy.
Pharmacodynamics
Targeted Gene Inhibition
The pharmacodynamic effects of Tofersen primarily stem from its selective binding to the messenger RNA (mRNA) generated by the mutated SOD1 gene. By targeting this mRNA, Tofersen effectively inhibits the translation process, reducing the production of the harmful SOD1 protein. This gene-specific inhibition serves as the cornerstone of Tofersen's therapeutic approach to treating ALS.
Reduction of Mutant SOD1 Protein
The presence of mutated SOD1 protein in ALS patients has been strongly associated with the disease's progression. Tofersen's pharmacodynamics aim to mitigate this progression by decreasing the levels of mutant SOD1 protein in affected motor neurons. By interfering with the translation process, Tofersen helps restore cellular balance and reduce the toxic effects associated with mutant SOD1 protein accumulation.
Preservation of Motor Neurons
Motor neuron degeneration is a hallmark of ALS, leading to the loss of muscle control and motor function. Tofersen's pharmacodynamics strives to preserve the integrity of motor neurons by targeting the underlying cause of their degeneration. By inhibiting the production of mutant SOD1 protein, Tofersen aims to slow down or halt the progressive deterioration of motor neurons, thereby potentially preserving muscle control and motor function for a longer duration.
Synergistic Effects with Supportive Care
In addition to its pharmacodynamic effects, Tofersen is often accompanied by a holistic approach to treating ALS, which involves implementing supportive care measures like physical therapy, occupational therapy, and respiratory support. By targeting the underlying cause of the disease, Tofersen can potentially enhance the effectiveness of these supportive care interventions, resulting in a more comprehensive and beneficial treatment plan for ALS patients.
Monitoring and Evaluation
Monitoring the pharmacodynamic effects of Tofersen is crucial to assess its efficacy and optimize treatment strategies. Biomarkers associated with the SOD1 pathway can serve as indicators of Tofersen's impact on mutant SOD1 protein levels. Regular assessments of motor function, muscle strength, and disease progression can help evaluate the therapeutic response and guide treatment decisions.
Safety and Adverse Events 
Safety Evaluation
During the clinical trials, rigorous monitoring and assessment were conducted to evaluate the safety of Tofersen. The results were encouraging, demonstrating a favorable safety profile for the drug. The trial participants encountered minimal and generally mild side effects, which were overshadowed by the potential advantages of the treatment (Miller et al., 2020). 
Mild and Transient Side Effects
The most commonly reported side effects associated with Tofersen were mild and transient in nature. These included injection site reactions, such as redness or discomfort at the injection site, which resolved quickly without intervention. Additionally, some participants reported mild flu-like symptoms, such as fever, fatigue, or muscle aches, which also resolved within a short period.
Absence of Serious Adverse Events
Crucially, the clinical trials did not report any serious adverse events directly attributable to Tofersen. This finding provides reassurance about the drug's safety profile and suggests that it can be well-tolerated by ALS patients. The absence of severe complications is an important factor in determining the suitability of a drug for long-term use.
Conclusion
Tofersen has emerged as a ray of hope for ALS patients, offering a promising treatment approach that targets the underlying genetic cause of the disease. This mini-review has highlighted the potential of Tofersen as an antisense oligonucleotide therapy designed to specifically tackle the genetic mutation responsible for ALS. Clinical trials have demonstrated its ability to effectively reduce SOD1 protein levels, resulting in improved motor function and survival outcomes in patients with certain genetic mutations.
The development and approval of Tofersen represent a significant milestone in ALS research, providing patients and healthcare professionals with a targeted therapeutic option. By directly addressing the genetic basis of ALS, Tofersen offers a unique approach that holds immense potential for slowing down disease progression and improving the quality of life for those affected by this devastating condition.
However, it is important to note that Tofersen is currently only approved for a subset of ALS patients with specific SOD1 mutations. Further research and clinical trials are necessary to explore its efficacy in other forms of ALS and to expand its availability to a wider patient population. Additionally, ongoing monitoring of long-term safety and efficacy is crucial to ensure the continued benefits of Tofersen treatment.
Despite these challenges, Tofersen represents a significant breakthrough in the field of ALS therapeutics. Its success has reinvigorated hope among ALS patients, their families, and the medical community. With continued research and advancements in genetic therapies, it is conceivable that Tofersen's success could pave the way for similar targeted treatments for other genetic forms of ALS and even other neurodegenerative diseases.
In summary, Tofersen has demonstrated its potential as a ray of hope for ALS patients by addressing the root cause of the disease through targeted genetic intervention. While there is still much to learn and accomplish in the field of ALS research and treatment, Tofersen represents a crucial step forward in the quest to improve the lives of individuals living with ALS and brings renewed optimism for the future of ALS therapeutics.
Conflict of Interest 
The Author declares that there is no conflict of interest.
References 
Bunton-Stasyshyn, R. K., Saccon, R. A., Fratta, P., & Fisher, E. M. (2014). SOD1 function and its implications for amyotrophic lateral sclerosis pathology. The Neuroscientist, 21(5), 519–529. 
Huai, J., & Zhang, Z. (2019). Structural properties and interaction partners of familial ALS-associated SOD1 mutants. Frontiers in Neurology, 10, 527.
Ekhtiari Bidhendi, E., Bergh, J., Zetterström, P., Forsberg, K., Pakkenberg, B., Andersen, P. M., … Brännström, T. (2018). Mutant superoxide dismutase aggregates from the human spinal cord transmit amyotrophic lateral sclerosis. Acta Neuropathologica, 136(6), 939–953. 
McCampbell, A., Cole, T., Wegener, A. J., Tomassy, G. S., Setnicka, A., Farley, B. J., … Miller, T. M. (2018). Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. Journal of Clinical Investigation, 128(8), 3558–3567. 
Miller, T., Cudkowicz, M., Shaw, P. J., Andersen, P. M., Atassi, N., Bucelli, R. C., … Ferguson, T. A. (2020). Phase 1–2 trial of antisense oligonucleotide tofersen for sod1 ALS. New England Journal of Medicine, 383(2), 109–119.